---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Special populations"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Special populations. Topics: Older adults: pharmacokinetics in healthy men aged 65 years or older; Sex: pharmacokinetics in healthy women; Age, sex, race, and body mass index: Launch-HTN subgroups; Race and ethnicity: first-in-human study population; 8 further topics. 12 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/special-populations"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Older adults: pharmacokinetics in healthy men aged 65 years or older

> “In part 4, there was no statistically significant difference between older adult and younger adult lorundrostat exposures (Table S4). The median T max value was earlier for older adult participants (1.0 h) vs. younger adult participants (1.5 h), and the mean t 1/2 value was slightly longer for older adult (11.4 h) than for younger adult (10.0 h) participants.”
> “In parts 3 and 4, the change from baseline of PAC and serum cortisol concentrations at 24 h after a single 100‐mg dose of lorundrostat was similar in male and female participants, as well as in those aged 18–55 years and aged ≥65 years.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.8-2"></a>

### Sex: pharmacokinetics in healthy women

> “In part 3 of the study, after a single 100‐mg dose of lorundrostat, there was no statistically significant difference between lorundrostat exposure in females and males (Table S4). The median T max values were comparable for female participants (1.3 h) and male participants (1.5 h), and the mean t 1/2 value was slightly longer for females (12.4 h) than for males (10.0 h).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.8-3"></a>

### Age, sex, race, and body mass index: Launch-HTN subgroups

> “The efficacy of lorundrostat for lowering BP was consistent across age, sex, race, BMI, and number of prescribed antihypertensive medications participants were taking (Figure 3).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

| Subgroup | Lorundrostat 50 mg, change in AOSBP at week 6 (mmHg) | Placebo, change in AOSBP at week 6 (mmHg) | Difference (90% CI) |
| --- | --- | --- | --- |
| Age ≥75 years | “-18.2” | “-6.6” | “-11.6 (-17.4, -5.8); p=0.0011” |
| Age 65 to 74 years | “-16.7” | “-9.8” | “-6.9 (-11.4, -2.4); p=0.0109” |
| Age <65 years | “-16.9” | “-7.6” | “-9.3 (-13.2, -5.4); p<0.0001” |
| Black or African American | “-15.1” | “-8.3” | “-6.7 (-11.6, -1.9); p<0.0222” |
| White | “-17.1” | “-8.0” | “-9.2 (-12.8, -5.6); p<0.0001” |
| Female | “-16.8” | “-7.4” | “-9.4 (-13.6, -5.3); p=0.0002” |
| Male | “-17.0” | “-8.2” | “-8.8 (-12.6, -5.1); p<0.0001” |
| BMI ≥30 kg/m2 | “-16.5” | “-6.9” | “-9.6 (-13.3, -5.8); p<0.0001” |
| BMI <30 kg/m2 | “-17.9” | “-9.5” | “-8.4 (-12.6, -4.3); p=0.0009” |

Source: [Mineralys Therapeutics press release, Launch-HTN subgroup analyses (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/80/mineralys-therapeutics-presents-subgroup-analyses-of-phase)

> “Launch-HTN is the largest global Phase 3 trial to date in uncontrolled or resistant hypertension, enrolling a diverse group of participants with high cardiovascular risk, including Black/African American (29%), adults aged ≥65 years (41%), women (47%), participants with obesity (63%), and those requiring three or more background antihypertensive medications (60%).”

Source: [Mineralys Therapeutics press release, Launch-HTN subgroup analyses (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/80/mineralys-therapeutics-presents-subgroup-analyses-of-phase)

<a id="topic-2.1.2.8-4"></a>

### Race and ethnicity: first-in-human study population

> “All participants were white and none were of Hispanic or Latino ethnicity.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.8-5"></a>

### Obesity: Target-HTN and Advance-HTN

> “Most notably, participants with obesity demonstrated greater BP lowering in response to lorundrostat. Individuals with a BMI greater than 30 randomized to 50 mg once daily of lorundrostat demonstrated a −16.7 mm Hg (90% CI, −25.5 to −7.9 mm Hg) change in systolic AOBP compared with placebo.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

| Key secondary end point | Result |
| --- | --- |
| Relationship of BMI to blood pressure reduction at 4 weeks | “No clear relationship” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-2.1.2.8-6"></a>

### Renal impairment: low urinary excretion of unchanged drug

> “After 7 days of once‐daily doses of lorundrostat, the fraction of the dose excreted in the urine as unchanged drug was low for all multiple‐dose levels, with mean values ranging between 2.3% and 2.6%.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.8-7"></a>

### Renal impairment: eGFR thresholds for enrollment

> “The key exclusion criteria were an estimated glomerular filtration rate (eGFR) of less than 45 mL/min/1.73 m2, a serum potassium level of greater than 5.0 mmol/L at screening or greater than 4.8 mmol/L at randomization, and a serum sodium level of less than 135 mmol/L at screening.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “Key exclusion criteria were serum potassium >5.0 mmol/l, serum sodium <135 mmol/l, eGFR <30 ml/min per 1.73 m2, and uncontrolled diabetes (glycated hemoglobin >10%).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-2.1.2.8-8"></a>

### Chronic kidney disease stages 1 to 3: Launch-HTN analysis

> “Placebo-adjusted reduction in AOSBP was -12.2 mmHg and -9.6 mmHg in participants without and with CKD, respectively (Table).”
> “Among participants receiving LOR 50mg, confirmed serum potassium >6.0 mmol/L occurred in 3 (2.4%) CKD participants and in none of the non-CKD participants. In LOR 50mg participants, mean cystatin C-based eGFR decreased by 7.3, 4.0 and 4.2 mL/min/1.73 m2 in those with CKD stage 1, 2, and 3, respectively, compared with 2.1 mL/min/1.73 m2 in those without CKD.”

Source: [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)

<a id="topic-2.1.2.8-9"></a>

### Chronic kidney disease with albuminuria: Explore-CKD

> “At baseline, mean automated office systolic blood pressure (AOSBP) was 149 mmHg, UACR (urinary albumin-to-creatinine ratio, an indicator of kidney protein loss) was 516.8 mg/g and mean estimated glomerular filtration rate (eGFR) was 43 mL/min/1.73m2 based on cystatin C.”

Source: [Mineralys Therapeutics press release, Explore-CKD publication (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/124/mineralys-therapeutics-announces-publication-of-phase-2)

> “In this study, hyperkalemia was the principal safety finding in participants with CKD and was the most common investigator-reported TEAE during the 4-week treatment period.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-2.1.2.8-10"></a>

### Hepatic impairment

No evidence found.

<a id="topic-2.1.2.8-11"></a>

### Hepatic disease: exclusion from the first-in-human study

> “Clinically significant endocrine, thyroid, hepatic, respiratory, gastro intestinal, neurological, renal, cardiovascular disease, or history of any significant psychiatric/psychotic illness disorder”

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="topic-2.1.2.8-12"></a>

### Pregnancy and lactation: exclusion from the trials

> “Women who are pregnant, plan to become pregnant, or are breastfeeding”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

> “Fertile male subjects and female subjects of childbearing potential, and their partners, must agree to use an acceptable method of contraception from study entry to 28 days after the last dose of study drug”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

> “healthy non‐pregnant and non‐lactating female Caucasian participants (part 3) aged 18–55 years (inclusive)”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.8-13"></a>

### Pediatric population

> “At least 18 years of age at the time of signing the informed consent form (ICF)”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
